ArchiMed, a private equity firm, completed an investment in PlasmidFactory, a gene and cell therapy specialist. Financial terms were not disclosed. “ArchiMed will act as our key catalyst for rapid and efficient expansion in a highly complex domain that few generalist investors, or a few healthcare investors, understand.” Schleef and his management team will remain in place, with the former rolling over a substantial portion of his proceeds in the group," Martin Schleef, PlasmidFactory Founder and CEO.